Jan 19, 2017
All the hard work and dedication in 2017 has successfully positioned Oramed to initiate a U.S. based multicenter 90-day treatment study under a FDA IND focused on the lowering of HbA1c in type 2 diabetic patients later this quarter. This is just one of many milestones achieved in 2017 and one of the forward-looking milestones we anticipate in the coming year.
….. for more http://www.oramed.com/oramed-pharmaceuticals-ceo-issues-letter-to-shareholders/
Source: PRNewswire https://www.prnewswire.com/news-releases/oramed-pharmaceuticals-ceo-issues-letter-to-shareholders-300585169.html